Technical analysis of Clene Inc. (CLNN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS).
Price Performance
| 1 month | -5.62% |
| 3 months | -35.77% |
| Year-to-date | -34.24% |
| 1 year | -37.44% |
| 3 years | -64.26% |
| 5 years | -97.60% |
52-Week Range
| 52-week High | $13.50 |
| 52-week Low | $3.25 |
| Avg Volume (90d) | 110K |
Technical Indicators
| SMA 50 | $4.80 |
| SMA 200 | $5.60 |
| Beta | 0.62 |
| 30-day Volatility (annualised) | 92.9% |
| Price vs SMA 50 | -19.7% |
| Price vs SMA 200 | -31.0% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $12.50 | |
| 2025-11 | $10.36 | -17.1% |
| 2025-12 | $5.87 | -43.3% |
| 2026-01 | $4.09 | -30.3% |
| 2026-02 | $5.23 | +27.9% |
| 2026-03 | $4.93 | -5.7% |
| 2026-04 | $6.16 | +24.9% |
| 2026-05 | $6.56 | +6.5% |
| 2026-06 | $6.16 | -6.1% |
| 2026-07 | $5.01 | -18.7% |
| 2026-08 | $4.28 | -14.6% |
| 2026-09 | $3.86 | -9.8% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $3.86 |
| Market Cap | $49M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -1.93 |
| EV / EBITDA | -3.38 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | -0.90 |
| Current Ratio | 3.07 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -27.14 |